From mutation to medicine: How neoantigen dendritic cell vaccines are reshaping cancer immunotherapy
A new generation of personalized cancer vaccines is taking shape through the use of neoantigen-based dendritic cell (DC) ...
To date, human anti-tumor vaccination has not delivered on its promises. Reasons for failure include tumor immune escape mechanisms, limited availability of tumor specific antigens, as well as failure ...
Scientists are turning venom, radioisotopes, engineered proteins, and AI into powerful new tools against cancer. From ...
InvestorsHub on MSN
Lunai Bioworks stock soars after securing first licensing deal for cancer therapy
Lunai Bioworks Inc. (NASDAQ:LNAI) jumped 19.7% in Tuesday’s premarket session after the AI-driven biotech firm announced it ...
A bold plan to supercharge immune cell 'spies' to better seek out and kill cancer cells has received a $17 million funding boost from the Australian ...
In an innovative new study of glioblastoma, scientists used artificial intelligence (AI) to reprogram cancer cells, converting them into dendritic cells (DCs), which can identify cancer cells and ...
12don MSN
The Cancer Immunology Data Engine: A big data platform for advancing cancer immunotherapy research
A clinical oncology research team at the LKS Faculty of Medicine, the University of Hong Kong (HKUMed), in collaboration with ...
Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial This was a single-center, open-label, single-arm, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback